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Edited by Ned ManteiAbstract We have investigated the physiological function of
type 2 methionine aminopeptidases (MetAP2) using Caenor-
habditis elegans as a model system. A homolog of human
MetAP2 was found in the C. elegans genome, which we termed
MAP-2. MAP-2 protein displayed methionine aminopeptidase
activity and was sensitive to inhibition by fumagillin. Down-
regulation of map-2 expression by RNAi led to sterility,
resulting from a defect in germ cell proliferation. These
observations suggest that MAP-2 is essential for germ cell
development in C. elegans and that this ubiquitous enzyme may
play important roles in a tissue speciﬁc manner.
 2004 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Germline development1. Introduction
Processing of N-terminal methionines is an essential post-
translational process in both prokaryotes and eukaryotes. This
process is catalyzed by a highly conserved family of enzymes
known as methionine aminopeptidases (MetAPs) [1,2]. In
prokaryotes such as Escherichia coli and Salmonella typhimu-
rium, a single methionine aminopeptidase gene has been
identiﬁed, the deletion of which is lethal [3,4]. In eukaryotes,
multiple genes have been found to encode this enzyme family.
In both yeast and humans, two proteins are known to possess
methionine aminopeptidase activity, which are known as type
1 (MetAP1) or type 2 (MetAP2) enzymes, respectively [5–7]. In
addition, a third isoform that appears to be speciﬁc for the
mitochondria has recently been discovered in mammals [8]. In* Corresponding author. Fax: +1-410-955-4620.
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doi:10.1016/j.febslet.2004.08.077yeast, knockout of eitherMAP1 orMAP2 causes a decrease in
growth rate while elimination of both genes is lethal [6], indi-
cating that the two MetAPs play redundant functions and are
together essential for yeast proliferation.
Recently, we and others identiﬁed mammalian MetAP2 as a
target for the angiogenesis inhibitors fumagillin and ovalicin
[9–16], suggesting a role for MetAP2 in angiogenesis. The
inhibition of angiogenesis by these natural products is due to
inhibition of endothelial cell proliferation. Fumagillin and
ovalicin show a surprising degree of selectivity; of a large
number of primary human cells tested, endothelial cells are
among the most sensitive to inhibition by fumagillin [17,18].
Thus, although methionine aminopeptidases appear to be uni-
versally important enzymes in prokaryotes and yeast, MetAP2
may play a more tissue and cell type speciﬁc role in higher
eukaryotes.
Despite the apparent importance of MetAP2 in angiogene-
sis, little is known about the function of MetAP2 proteins in
vivo. To better understand the physiological function of type 2
MetAPs in a multicellular organism, we turned to the C. ele-
gans for the ease with which genetic manipulations can be
carried out in the worm. We found a single predicted ORF
(Y116A8A.9) with a high degree of similarity to human Me-
tAP2 in the genome of C. elegans, which we termed map-2. We
cloned the predicted C. elegans map-2 gene, and overexpressed
and puriﬁed MAP-2 protein from baculovirus-driven insect
cells. We show that MAP-2 is a fully active methionine ami-
nopeptidase and is sensitive to inhibition by fumagillin. We
used RNA interference (RNAi) to inhibit the expression of
map-2 and observed defects in gonad development. Further
analysis of this defect suggests a critical role for map-2 in germ
cell proliferation in C. elegans.2. Materials and methods
2.1. Strains and culture conditions
Worm strains used were derived from the wild-type Bristol strain N2
and were cultured using standard techniques as described [19]. In ad-
dition to N2, the following strains and mutations were used: DG1576
tnIs5[lim-7::GFP; rol-6(su1006d)] [20] and NL2098 rrf-1(pk1417) I
[21].
2.2. Puriﬁcation of recombinant MAP-2 protein
The full-length map-2 gene was PCR ampliﬁed from the ProQuest
C. elegans cDNA library (Invitrogen) using primers 50-GCGAATTC-
ATGCCACCAGCAAACGGAAAAAAG-30 and 50-GCCTCGAG-
TTAATAATCATCTCCACGGGAG-30, then cloned into theblished by Elsevier B.V. All rights reserved.
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construct was transfected into packaging cell line Sf9 (Pharmingen).
Recombinant P2 baculovirus carrying map-2 with a 6xHis tag was
used to infect Hi5 insect cells. Sf9 and Hi5 monolayer cells were
maintained in Grace’s medium (Gibco). His-tagged MAP-2 was
puriﬁed from Hi5 cells using a Talon metal aﬃnity column (Clon-
tech) and used for further enzymatic assays or stored at )80 C.
2.3. RNAi
Gateway recombinational cloning (Invitrogen) was used to gener-
ate RNAi template constructs. For full-length map-2 and F53B6.5,
entry clones were obtained from the Vidal lab ORFeome resource
[22]. For map-2 50 and 30 regions, entry clones were generated from
fragments PCR ampliﬁed from the ProQuest C. elegans cDNA li-
brary (Invitrogen) with the following primers: for map-2 50 region:
50-GGGGACAAGTTTGTACAAAAAAGCAGGCTTGCCACCAG-
CAAACGGAA-30 and 50-GGGGACCACTTTGTACAAGAAAGC-
TGGGTTTCACGGACTGCTT CGAC-30, and for map-2 30 region:
50-GGGGACAAGTTTGTACAAAAAAGCAGGCTACCAATGCC-
GGAATCAAAGAA-30 and 50-GGGGACCACTTTGTACAAGAA-
AGCTGGGTAATAATCATCTCCACGGGAGAC-30. The inserts
in each entry clone were transferred into the pDEST-pPD129.36
vector, which contains juxtaposed T7 promoter sites ﬂanking the
insert site [23]. From these constructs, linear template DNA was
generated by PCR using primers 50-TGGATAACCGTATTACC-
GCC-30 and 50-GTTTTCCCAGTCACGACGTT-30. Double stran-
ded RNA was then generated using the MEGAscript in vitro
transcription kit (Ambion, Austin, TX). Animals were injected fol-
lowing standard procedure [19] and progeny produced more than
24 h after injection of dsRNA were examined.2.4. DNA staining
DNAwas stained with propidium iodide as previously described [24].
2.5. Ovalicin feeding
Between 1 and 10 L4 age N2 animals were placed in S-medium [19]
with E. coli OP50 in 96-well plates. Diﬀerent amounts of ovalicin
(1:10–1:1 000 000 serial dilutions from a 10 mM stock) were added to
each well. As ovalicin is unstable at lower pH levels, the pH of the S-
medium was increased to 7. After growth at 20 C for 3–5 days, the F1
generation was examined for phenotypic abnormalities.Fig. 1. Identiﬁcation of C. elegans homologs of type I and II methionine
S. cerevisiae MetAP proteins and their closest homologs in C. elegans. Protei
their amino acid identity with the human METAP proteins. (B) Conservation
The numbers indicate the amino acid position within each protein sequence.
metal-binding residues critical for aminopeptidase activity. In both panels, C
Y116A8a.9, respectively.2.6. Ovalicin injection
Young adult N2 animals were injected with 100 and 1000 lM ﬁnal
concentrations of ovalicin in M9 buﬀer [19], and their progeny was
examined for phenotypic abnormalities.
2.7. Western blotting
To obtain C. elegans protein samples, wild-type and map-
2(RNAi) animals were lysed by boiling in 1· Laemmli sample buﬀer
[25]. Protein samples were subjected to SDS–PAGE and immu-
noblotted using standard techniques [25]. Antibodies used were
polyclonal anti-human MetAP2, that was shown to react with the
worm MetAP2 at 1:1000 dilution, and anti-Tubulin ab3194 (Abcam)
at 1:1000 dilution.3. Results
3.1. Identiﬁcation of MetAP1 and MetAP2 orthologs in the
genome of C. elegans
BLAST searches of the C. elegans genome identiﬁed one
predicted ORF similar to yeast and human MetAP1
(Y37E11AL.7), and four predicted ORFs similar to yeast and
human MetAP2 (Y116A8a.9, F53B6.5, T27A8.3 and
W08E12.7) (Fig. 1A). Several lines of evidence indicate that
these ORFs are predicted correctly. First, we were able to PCR
amplify fragments of the expected size from a cDNA library
using primers directed against the predicted 50 and 30 ends of
the genes (not shown). Second, cDNAs exist that correspond
to the predicted structures of Y37E11AL.7, Y116A8a.9 and
W08E12.7 (http://www.wormbase.org, release WS123). Fi-
nally, the sequences between the putative start and stop of
F53B6.5 and W08E12.7 have been veriﬁed by the ORFeome
project [22].
Based upon sequence similarity, Y116A8a.9 is a strong
candidate to be a functional MetAP2 enzyme. Of the four
MetAP2 related ORFs, only Y116A8a.9 has high overall
similarity to mammalian MetAP2 (Fig. 1A), is predicted toaminopeptidases. (A) Sequence comparison between the human and
ns were aligned using the ClustalW algorithm and colored according to
of residues in the active site involved in the binding of two metal ions.
Green box: the histidine covalently modiﬁed by fumagillin. Red boxes:
eMAP-1 and CeMAP-2 refer to the predicted ORFs Y37E11AL.7 and
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karyotic MetAPs (Fig. 1A), and contains all ﬁve critical resi-
dues in the active site of human and yeast MetAP2 proteins
involved in the binding of two metal ions (Fig. 1B). Therefore,
based upon the high degree of similarity between MetAP1 and
Y37E11AL.7, and between MetAP2 and Y116A8a.9, we
named the corresponding genes map-1 and map-2, respectively
(for methionine aminopeptidase), and selected Y116A8a.9 as
the likely worm MetAP2 analog for further analysis.
3.2. MAP-2 is an active methionine aminopeptidase and is
capable of binding to fumagillin irreversibly
To characterize MAP-2 biochemically, we overexpressed
His-tagged MAP-2 in baculovirus-driven insect cells and pu-
riﬁed the recombinant protein to near homogeneity with the
help of the Talon metal aﬃnity resin. Recombinant MAP-2 is
active as a methionine aminopeptidase, as demonstrated by its
ability to cleave a methionine-containing oligopeptide sub-
strate, Met–Ala–Ala–Met (Fig. 2A) [12,26]. MAP-2 is similar
in activity to human MetAP2, as judged by the amount of
substrate cleaved at identical concentrations of these proteins
(data not shown). We next determined whether MAP-2 is
sensitive to fumagillin. As shown in Fig. 2A, the clinically
tested fumagillin analog, TNP-470, inhibited MAP-2 activity
in a dose-dependent manner. Using 10 nM of recombinant
MAP-2, the IC50 value for TNP-470 was determined to be 310
nM. In comparison, the human enzyme has an IC50 value of
about 10 nM under the same assay conditions. Thus, MAP-2 is
signiﬁcantly less sensitive to TNP-470. Although all key resi-
dues known to be involved in direct contact with fumagillin
based on the crystal structure [11] are conserved betweenFig. 2. MAP-2 is a functional methionine aminopeptidase and is in-
hibited irreversibly by fumagillin. (A) Inhibition of worm MAP-2 by
TNP-470. Varying concentrations of TNP-470 were incubated with 10
nM of MAP-2 for 1 h before the enzyme activity was determined. The
relative activity was obtained by normalizing enzyme activity to that
determined in the absence of TNP-470. (B) MAP-2 binds to fumagillin
irreversibly. Near-Western blot was performed using recombinant
worm MAP-2 (Lanes 1 and 2) and human MetAP2 (Lanes 3 and 4).
Lane 1, MAP-2+Biotin-fumagillin; Lane 2, MAP-2+Biotin-fumagil-
lin +TNP-470; Lane 3, hMetAP2+Biotin-fumagillin; Lane 4, hMet-
AP2+Biotin-fumagillin +TNP-470.MAP-2 and human MetAP2, sequence divergence exists for
residues in close proximity to those residues. Examples of se-
quence divergence include Asp178, Ala298, and Val416 in
MAP-2 in place of Asn214, Gly334 and Ile450 in hMetAP2,
respectively. These diﬀerences in sequence may account for the
diﬀerence in sensitivity to TNP-470 between MAP-2 and hu-
man MetAP2 proteins.
Fumagillin was previously shown to bind to human and
yeast MetAP2 by forming a covalent bond between the drug
and protein through the opening of the spiro-epoxide of
fumagillin by a histidine residue in the active site of MetAP2
[10–12]. As this histidine is conserved in MAP-2, we deter-
mined whether fumagillin is bound covalently to MAP-2 using
the ‘‘Near Western’’ blot analysis developed previously [16].
Upon incubation of MAP-2 or human MetAP2 with a biotin-
fumagillin conjugate, the reaction mixture was subjected to
reducing and denaturing SDS–PAGE. The biotin-fumagillin
conjugate remains attached to the MetAPs only when bound
covalently. As we have previously shown, biotin-fumagillin is
bound covalently to human MetAP2 (shown here as a doublet
due to proteolysis upon storage) (Fig. 2B, Lane 3). This co-
valent binding is competed by an excess amount of free TNP-
470 (Fig. 2B, Lane 4). Like human MetAP2, MAP-2 is also
bound to fumagillin covalently and as expected, its binding to
MAP-2 is sensitive to competition by TNP-470 (Fig. 2B, Lanes
1 and 2). These observations indicate that MAP-2 is highly
similar to human MetAP2 in its interaction with the fumagillin
family of inhibitors.
3.3. map-2 is required for the development of the C. elegans
gonad
As a ﬁrst attempt to determine the role of map-2 in C. ele-
gans, we treated worms with ovalicin by including the drug in
the growth media or injection (see Section 2). However, no
phenotypic change was seen upon treatment with ovalicin.
Since ovalicin contains such unstable functional groups as the
epoxide that is critical for its activity, it is unclear whether the
lack of eﬀect of ovalicin reﬂects the absence of an in vivo role
for methionine aminopeptidase activity in C. elegans or is due
to the inability of an active drug to reach map-2 expressing
cells.
As an alternative approach to inhibiting map-2 activity by
ovalicin treatment, we examined the eﬀect of interfering with
map-2 expression by RNAi. Of the 4 MetAP2 related C. ele-
gans sequences, F53B6.5 and T27A8.3 are over 99% identical
to each other at the base pair level, and are also 91% identical
to map-2 over a 350 bp region in the 30 region of map-2 (base
pairs 845–1195). Given these high levels of similarity, dsRNA
directed against the 30 region of map-2 could aﬀect the tran-
script levels of all three genes [27,28]. Therefore, we determined
if RNAi against the 50 region of map-2, which shares no ho-
mology with F53B6.5 or T27A8.3, could eﬀectively interfere
with map-2 expression. We injected dsRNA corresponding to
full-length map-2, and the 50 and 30 regions independently
(Fig. 3A and methods). The progeny of injected animals were
lysed and subjected to Western blotting with an antibody
raised against human MetAP2 that we found to cross-react
with recombinant worm MAP-2 protein. In control lysates,
this antibody recognizes a protein of approximately 50 kDa,
which corresponds to the predicted size of MAP-2 (Fig. 3A,
Lanes 1 and 5). By contrast, no protein was detected in any of
the map-2 RNAi treated animals (Fig. 3A, Lanes 2–4). Thus,
Fig. 3. map-2 RNAi blocks germline development. (A) Western blot showing cross reactivity of an anti-METAP2 antibody with a protein of expected
size in wild-type C. elegans lysates (Lanes 1 and 5) but not in protein lysates from map-2(RNAi) animals (Lanes 2–4). Lane 1: lysate from progeny of
animals injected with TE buﬀer. Lanes 2–4: lysate from progeny of animals injected with dsRNA corresponding to the fragments of map-2 shown
below the blots. Lane 5: untreated wild-type N2 lysate. Bottom panel shows staining of the same samples with an anti-tubulin antibody as a loading
control. Gray and black areas in drawing of map-2 indicate regions of 45% and 91% identity with F53B6.5 and T27A8.3, respectively. (B) Nomarski
DIC microscopy images of wild-type C. elegans (left panels) and map-2(RNAi) animals (right panels). a and b show late L3/early L4 animals (as
judged by vulva development) and c and d show adult animals. (C) Propidium iodide DNA staining of wild type adult animals (a,c) and map-
2(RNAi) adult animals (b,d). a and b are an overview of an entire gonad arm, while c and d show a higher magniﬁcation. Small panels show two
typical pachytene nuclei from the wild-type gonad and examples of the discrete foci (arrow in d) or less condensed (arrowhead in d) nuclei observed in
map-2(RNAi) animals.
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2 expression.
In addition to Western blot analysis, the progeny of injected
wild-type animals was examined for mutant phenotypes. In all
cases, embryos appeared to develop normally and hatched at
similar times as wild-type control embryos. No delays in larval
development were observed, and movement of RNAi animals
was normal, indicating no obvious abnormalities in nervous
system or muscle development. However, each of the three
RNAi injections caused larvae to develop into sterile adults.
Examination of the map-2 sterile animals by Nomarski DIC
microscopy showed that these animals have small gonad arms,
with few, if any, germ cells present. Thus, map-2 appears to be
required for C. elegans gonad development.
As RNAi against the 50 region of map-2 interfered as eﬃ-
ciently with map-2 expression as RNAi against full length or 30
map-2, and all three RNAi constructs produced the same
phenotype, the 50 region was used in all further RNAi exper-
iments.
3.4. Inactivation of map-2 causes a defect in germ-cell
proliferation and diﬀerentiation
To examine the defects caused by map-2 RNAi in more
detail, the diﬀerent larval stages of map-2(RNAi) animals were
studied both by Nomarski DIC microscopy and by staining
with the DNA intercalating dye propidium iodide (P.I.). All
somatic tissues appeared to form normally, including cells ofthe uterus, gut, hypodermis and pharynx – which was actively
pumping. In contrast, neither arm of the gonad developed to
the wild type size. Although a small number of germ cells are
formed, diﬀerentiation of sperm and oocytes was not observed
(Fig. 3B, compare panels a and c with panels b and d). In
addition, condensation of the DNA of the germ cells was ab-
normal. In wild type animals, germ cells are formed at the
distal end of the gonad. Moving proximally, germ cells enter
meiosis and arrest at pachytene of prophase of meiosis I until
around the time they pass the U-shaped ﬂexure in the gonad.
At this point the chromosomes condense further as the germ
cells enter diakinesis and oocytes are formed. In map-2(RNAi)
animals, the typical threadlike appearance of the paired ho-
mologous chromosomes in pachytene (Fig. 3C, panel c) is not
observed. Instead, some germ cells appear only partly con-
densed, while the DNA in others appears as a number of
discrete foci (Fig. 3C, panel d). In the latter case, more than 6
foci are observed, indicating a possible defect in chromosome
pairing. Thus, map-2 appears to be essential for germ-cell
proliferation and diﬀerentiation.
3.5. map-2 RNAi causes a cell-intrinsic defect in germ cell
proliferation
The C. elegans adult reproductive system consists of two
gonadal arms, each composed of 5 pairs of somatic sheath
cells, ﬁlled with germ cells in various stages of development
(reviewed in [29]). Each gonad arm is capped at its distal end
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development of the germline. The lack of germ cell prolifera-
tion in map-2(RNAi) animals could be due to a cell intrinsic
defect, or to a defect in these somatic gonadal tissues. To
distinguish between these possibilities, we examined sheath cell
formation in map-2(RNAi) animals and performed map-
2(RNAi) in a mutant background in which somatic cells are
not aﬀected by RNAi.
To determine if gross abnormalities in the somatic gonad
exist in map-2(RNAi) animals, we examined a GFP marker
for development of the sheath cells. In wild-type animals
during gonadogenesis and in adults, the lim-7::GFP reporter
gene is expressed in the 4 most distal sheath cell pairs (Fig. 4A
and C) [20]. Similarly, in map-2 RNAi animals, we observed
expression of lim-7::GFP at the distal end of the gonad arms
(Fig. 4B and D). Thus, map-2(RNAi) animals express a
marker for gonad development in the appropriate tissue at the
correct stages of development.
To determine if map-2 functions in a germ cell-intrinsic
fashion, we examined the eﬀect of inactivating map-2 by RNAi
in an rrf-1 mutant background. The rrf-1 gene encodes an
RNA-directed RNA polymerase required for the ampliﬁcation
of the RNAi signal speciﬁcally in somatic tissues [21]. Thus,
rrf-1 mutant animals lack an RNAi response in the soma. If
map-2 function is restricted to the germline, map-2 RNAi in
rrf-1 mutant animals would be expected to produce an iden-
tical phenotype to map-2 RNAi in wild-type animals. We in-
jected map-2 dsRNA into rrf-1(pk1417) mutant animals and
examined their progeny. As with map-2 RNAi in wild-type
animals, map-2 RNAi in rrf-1 mutants produced 100% sterile
oﬀspring. Both by Nomarski DIC microscopy of live animals
and by PI staining of the DNA of ﬁxed adults, the phenotype
of the rrf-1; map-2(RNAi) animals was indistinguishable from
that observed upon map-2 RNAi in a wild-type background.
This indicates that map-2 does not play an essential role in
somatic tissues.
Although RNAi by injection has been shown to phenocopy
the eﬀect of many strong loss-of-function alleles [27,28], it re-
mains possible that certain developmental stages or tissues of
C. elegans are refractory to map-2 RNAi, and that lack ofFig. 4. lim-7::GFP is expressed in sheath cells of map-2(RNAi) animals. Nom
microscopy images (C, D) of a wild type adult animal (left panels) and a magonad development is not the full map-2 null phenotype.
However, the fact that map-2 RNAi dramatically reduces
MAP-2 protein expression argues against this possibility.
Therefore, based upon our ﬁndings we conclude that map-2
most likely acts in the germline and regulates germline devel-
opment and/or proliferation in a cell-intrinsic fashion in
C. elegans.4. Discussion
In the present study, we examined the role of type 2 MetAPs
in the development of C. elegans using RNA interference. We
identiﬁed a predicted ORF, which we termed map-2, with a
high degree of similarity with human and yeast MetAP2 over
the entire length of the protein. Biochemical analysis demon-
strates that MAP-2 protein possesses methionine aminopepti-
dase activity, and is sensitive to inhibition by the fumagillin
analog TNP-470 like its human and yeast counterparts. Our
analysis of the loss-of-function phenotype of the map-2 gene
indicates that map-2 is required for germ-cell proliferation in a
tissue-speciﬁc manner.
Although the biochemical function of type 2 MetAPs – the
removal of amino-terminal methionines – appears to be a
general one, inactivation of MetAP2 has been shown to cause
tissue-speciﬁc defects in diﬀerent organisms. For example,
most mouse cells are sensitive to inhibition by TNP-470 [30].
By contrast, TNP-470 is highly selective toward human en-
dothelial cells without signiﬁcantly aﬀecting other cell types
[18,30,31]. In Drosophila, weak alleles of the MetAP2 ortholog,
DMAP2, cause a roughened eye phenotype, with ommatidial
rotation defects and a reduced size of the ventral half of the eye
[32]. In addition, the L5 wing vein is often abnormally bran-
ched with extra vein material. Putative loss-of-function alleles
are lethal, but analysis of mutant cell clones in the eye indicates
an essential role for DMAP2 in cell growth. Thus, in four
diﬀerent model systems, MetAP2 appears to act in a distinct
set of tissues.
The diﬀerent phenotypes observed in various model organ-
isms in response to downregulation of MetAP2 level or activityarski DIC microscopy images (A, B) and corresponding ﬂuorescence
p-2(RNAi) adult animal (right panels).
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same species have diverged in their dependence on MetAP2.
How might this divergence come about? A few possibilities
exist. First, MetAP2 in higher eukaryotes may have distinct
substrate speciﬁcity, and the particular protein substrates may
vary between organisms. Given the general nature of methio-
nine aminopeptidase activity and conservation in sequence, it
appears unlikely that such speciﬁcity of MetAP2 has devel-
oped. A second possibility is that MetAP2 targets a large
similar set of proteins in each organism and the diﬀerence in
dependence on MetAP2 reﬂects a diﬀerence in dependence
upon the homologous MetAP2 substrates. Finally, it is pos-
sible that the critical MetAP2 targets are the same in each
organism, but the biological processes or pathways in which
these proteins function diﬀer in each organism.
In addition to their function as methionine aminopeptidases,
eukaryotic MetAP2 proteins have evolved to regulate protein
synthesis by preventing the phosphorylation and inactivation
of the a-subunit of eukaryotic initiation factor-2 (eIF2) [33,34].
This function appears to be mediated by a lysine rich domain
and a glycosylation site in an N-terminal extension of the
protein that is speciﬁc to eukaryotic MetAP2 [35,36]. Although
C. elegans MAP-2 shares the N-terminal extension with other
eukaryotic MetAP2 enzymes, the lysine rich domain and the
glycosylation site are poorly conserved. It is unclear therefore
whether MAP-2 has a function in regulating eIF2.
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